Market open
Rani Therapeutics/$RANI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rani Therapeutics
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
Ticker
$RANI
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
140
Website
RANI Metrics
BasicAdvanced
$37M
-
-$1.05
-
-
Price and volume
Market cap
$37M
52-week high
$8.75
52-week low
$1.03
Average daily volume
183K
Financial strength
Current ratio
1.495
Quick ratio
1.411
Long term debt to equity
379.33
Total debt to equity
850.53
Interest coverage (TTM)
-9.85%
Management effectiveness
Return on assets (TTM)
-65.57%
Return on equity (TTM)
-391.10%
Valuation
Price to revenue (TTM)
31.025
Price to book
18.8
Price to tangible book (TTM)
18.8
Price to free cash flow (TTM)
-0.892
Growth
Earnings per share change (TTM)
-20.85%
3-year revenue growth (CAGR)
-27.67%
3-year earnings per share growth (CAGR)
35.21%
What the Analysts think about RANI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Rani Therapeutics stock.
RANI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
RANI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
RANI News
AllArticlesVideos
Rani Therapeutics Holdings, Inc. (RANI) Q4 2024 Earnings Call Transcript
Seeking Alpha·1 week ago
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
GlobeNewsWire·1 week ago
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
GlobeNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Rani Therapeutics stock?
Rani Therapeutics (RANI) has a market cap of $37M as of April 08, 2025.
What is the P/E ratio for Rani Therapeutics stock?
The price to earnings (P/E) ratio for Rani Therapeutics (RANI) stock is 0 as of April 08, 2025.
Does Rani Therapeutics stock pay dividends?
No, Rani Therapeutics (RANI) stock does not pay dividends to its shareholders as of April 08, 2025.
When is the next Rani Therapeutics dividend payment date?
Rani Therapeutics (RANI) stock does not pay dividends to its shareholders.
What is the beta indicator for Rani Therapeutics?
Rani Therapeutics (RANI) does not currently have a Beta indicator.